126 related articles for article (PubMed ID: 7216614)
1. Design and synthesis of potent in vivo antagonists of oxytocin.
Bankowski K; Manning M; Seto J; Haldar J; Sawyer WH
Int J Pept Protein Res; 1980 Nov; 16(5):382-91. PubMed ID: 7216614
[TBL] [Abstract][Full Text] [Related]
2. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
Manning M; Kruszynski M; Bankowski K; Olma A; Lammek B; Cheng LL; Klis WA; Seto J; Haldar J; Sawyer WH
J Med Chem; 1989 Feb; 32(2):382-91. PubMed ID: 2913298
[TBL] [Abstract][Full Text] [Related]
3. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
4. Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
Manning M; Cheng LL; Klis WA; Balaspiri L; Olma A; Sawyer WH; Wo NC; Chan WY
J Med Chem; 1995 May; 38(10):1762-9. PubMed ID: 7752199
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
[TBL] [Abstract][Full Text] [Related]
6. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
Manning M; Miteva K; Pancheva S; Stoev S; Wo NC; Chan WY
Int J Pept Protein Res; 1995; 46(3-4):244-52. PubMed ID: 8537178
[TBL] [Abstract][Full Text] [Related]
8. Synthetic antagonists of in vivo responses by the rat uterus to oxytocin.
Lowbridge J; Manning M; Seto J; Haldar J; Sawyer WH
J Med Chem; 1979 May; 22(5):565-9. PubMed ID: 458806
[TBL] [Abstract][Full Text] [Related]
9. Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.
Manning M; Olma A; Klis WA; Seto J; Sawyer WH
J Med Chem; 1983 Nov; 26(11):1607-13. PubMed ID: 6631916
[TBL] [Abstract][Full Text] [Related]
10. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
11. Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.
Manning M; Olma A; Klis WA; Kolodziejczyk AM; Seto J; Sawyer WH
J Med Chem; 1982 Jan; 25(1):45-50. PubMed ID: 7086821
[TBL] [Abstract][Full Text] [Related]
12. 125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand.
Elands J; Barberis C; Jard S; Tribollet E; Dreifuss JJ; Bankowski K; Manning M; Sawyer WH
Eur J Pharmacol; 1988 Mar; 147(2):197-207. PubMed ID: 2835249
[TBL] [Abstract][Full Text] [Related]
13. [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),4-valine,-8-D-arginine]vasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin.
Lowbridge J; Manning M; Haldar J; Sawyer WH
J Med Chem; 1978 Mar; 21(3):313-5. PubMed ID: 628009
[TBL] [Abstract][Full Text] [Related]
14. Receptors for neurohypophyseal hormones along the rat nephron: 125I-labelled d(CH2)5[Tyr(Me)2, Thr4, Orn8, Tyr-NH(2)9] vasotocin binding in microdissected tubules.
Ammar A; Schmidt A; Semmekrot B; Roseau S; Butlen D
Pflugers Arch; 1991 Apr; 418(3):220-7. PubMed ID: 1830390
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of V1a vasopressin receptors in the rat cortical collecting duct.
Ammar A; Roseau S; Butlen D
Am J Physiol; 1992 Apr; 262(4 Pt 2):F546-53. PubMed ID: 1533099
[TBL] [Abstract][Full Text] [Related]
17. Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7.
Pavo I; Slaninova J; Klein U; Fahrenholz F
J Med Chem; 1994 Jan; 37(2):255-9. PubMed ID: 7507528
[TBL] [Abstract][Full Text] [Related]
18. The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin.
Sawyer WH; Haldar J; Gazis D; Seto J; Bankowski K; Lowbridge J; Turan A; Manning M
Endocrinology; 1980 Jan; 106(1):81-91. PubMed ID: 7349976
[TBL] [Abstract][Full Text] [Related]
19. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Kolodziejczyk AM; Seto J; Sawyer WH
J Med Chem; 1981 Jun; 24(6):701-6. PubMed ID: 7252979
[TBL] [Abstract][Full Text] [Related]
20. 2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.
Lammek B; Bankowski K; Misicka A; Manning M; Seto J; Sawyer WH
J Med Chem; 1989 Jan; 32(1):244-7. PubMed ID: 2909737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
